secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2025-09-18T23:59:59+00:00
Accession:  0001493152-25-013970
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Telomir-1 inhibits KDM5 demethylase families in vitro, expanding epigenetic targeting
--------------------------------------------------------------------------------

- Telomir-1 inhibits KDM5A, KDM5B, and KDM5C in vitro, blocking silencing of tumor suppressor genes.
- Adds to prior activity on KDM2/KDM6 families and DNA methylation, unique among epigenetic therapies.
- Telomir-1 spared GCN5L2 acetyltransferase, indicating potential for reduced systemic toxicity.
- IND-enabling studies and GMP scale-up ongoing; additional preclinical evaluations in cancer and aging.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000149315225013970/0001493152-25-013970-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000149315225013970/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-013970

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer